Literature DB >> 23695800

A quantum dot probe conjugated with aβ antibody for molecular imaging of Alzheimer's disease in a mouse model.

Li Feng1, Hong-Yu Long, Ren-Kai Liu, Dan-Ni Sun, Chao Liu, Li-Li Long, Yi Li, Si Chen, Bo Xiao.   

Abstract

The treatment of Alzheimer's disease (AD) has been hampered by a lack of sensitive and specific non-invasive diagnostic methods. Quantum dots (QD) are nano-crystals with unique photo-physical properties that bypass some of the limitations of conventional dyes and imaging tools. This study is aimed to evaluate the fluorescence properties of a QD probe conjugated with an anti-Aβ antibody (QD-Aβ-Ab). Healthy mice and mice bearing mutated human APP695swe and APP717 V-F transgenes received intracerebroventricular injection of the probe for subsequent imaging. Immunohistochemistry revealed that Aβ1-42 was distributed in the hippocampus CA1 area in the APP transgenic mice. Fluorescence microscopy demonstrated that fluorescence was mainly observed in the hippocampus area, the cerebral cortex, sagittal septum and striatum of APP transgenic mice. In vivo imaging of mice receiving the QD-Aβ-Ab probe showed that healthy mice exhibited a narrow range of fluorescence and lower fluorescence intensity compared with APP transgenic mice. The mean fluorescence intensity of brain tissues of healthy C57BL mice was 12.3784 ± 3.9826, which was significantly lower than that of 10- and 16-month-old APP transgenic mice (45.03 ± 2.66 and 46.69 ± 3.22, respectively; P < 0.05). In this study we present the first direct evidence that QD-Aβ-Ab conjugate probes can track in vivo state of Aβ accumulation in mice and the findings suggest that such probes may be of potential use for early molecular diagnostic imaging of AD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695800     DOI: 10.1007/s10571-013-9943-6

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  23 in total

1.  Long-term multiple color imaging of live cells using quantum dot bioconjugates.

Authors:  Jyoti K Jaiswal; Hedi Mattoussi; J Matthew Mauro; Sanford M Simon
Journal:  Nat Biotechnol       Date:  2002-12-02       Impact factor: 54.908

2.  Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking.

Authors:  Maxime Dahan; Sabine Lévi; Camilla Luccardini; Philippe Rostaing; Béatrice Riveau; Antoine Triller
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

3.  Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.

Authors:  Kensaku Kasuga; Takayoshi Tokutake; Atsushi Ishikawa; Tsuyoshi Uchiyama; Takahiko Tokuda; Osamu Onodera; Masatoyo Nishizawa; Takeshi Ikeuchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06       Impact factor: 10.154

Review 4.  [Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives?].

Authors:  F Checler; L Buée
Journal:  Ann Pharm Fr       Date:  2009-02-28

5.  [Diagnosis and therapy of Alzheimer's disease: what's important for the family doctor?].

Authors:  R Perneczky; A Kurz
Journal:  MMW Fortschr Med       Date:  2008-12-04

6.  Visual memory predicts Alzheimer's disease more than a decade before diagnosis.

Authors:  C H Kawas; M M Corrada; R Brookmeyer; A Morrison; S M Resnick; A B Zonderman; D Arenberg
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

7.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Authors:  Peder Buchhave; Lennart Minthon; Henrik Zetterberg; Asa K Wallin; Kaj Blennow; Oskar Hansson
Journal:  Arch Gen Psychiatry       Date:  2012-01

8.  Frequency of stages of Alzheimer-related lesions in different age categories.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

Review 9.  Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.

Authors:  Delphine Boche; Nathan Denham; Clive Holmes; James A R Nicoll
Journal:  Acta Neuropathol       Date:  2010-07-15       Impact factor: 17.088

10.  In vivo cancer targeting and imaging with semiconductor quantum dots.

Authors:  Xiaohu Gao; Yuanyuan Cui; Richard M Levenson; Leland W K Chung; Shuming Nie
Journal:  Nat Biotechnol       Date:  2004-07-18       Impact factor: 54.908

View more
  7 in total

Review 1.  Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.

Authors:  Howard E Gendelman; Vellareddy Anantharam; Tatiana Bronich; Shivani Ghaisas; Huajun Jin; Anumantha G Kanthasamy; Xinming Liu; JoEllyn McMillan; R Lee Mosley; Balaji Narasimhan; Surya K Mallapragada
Journal:  Nanomedicine       Date:  2015-01-31       Impact factor: 5.307

2.  Upregulation and Diverse Roles of TRPC3 and TRPC6 in Synaptic Reorganization of the Mossy Fiber Pathway in Temporal Lobe Epilepsy.

Authors:  Chang Zeng; Pinting Zhou; Ting Jiang; Chunyun Yuan; Yan Ma; Li Feng; Renkai Liu; Weiting Tang; Xiaoyan Long; Bo Xiao; Fafa Tian
Journal:  Mol Neurobiol       Date:  2014-09-12       Impact factor: 5.590

Review 3.  Nanotechnology in neurology: Genesis, current status, and future prospects.

Authors:  Paurush Ambesh; Daniel Gregory Angeli
Journal:  Ann Indian Acad Neurol       Date:  2015 Oct-Dec       Impact factor: 1.383

4.  Impairments of spatial learning and memory following intrahippocampal injection in rats of 3-mercaptopropionic acid-modified CdTe quantum dots and molecular mechanisms.

Authors:  Tianshu Wu; Keyu He; Shengjun Ang; Jiali Ying; Shihan Zhang; Ting Zhang; Yuying Xue; Meng Tang
Journal:  Int J Nanomedicine       Date:  2016-06-10

Review 5.  Nanomedicines in the Management of Alzheimer's Disease: Current View and Future Prospects.

Authors:  Hitesh Chopra; Shabana Bibi; Inderbir Singh; Mohammad Amjad Kamal; Fahadul Islam; Fahad A Alhumaydhi; Talha Bin Emran; Simona Cavalu
Journal:  Front Aging Neurosci       Date:  2022-07-08       Impact factor: 5.702

6.  Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme.

Authors:  Daishi Yui; Yoichiro Nishida; Tomoko Nishina; Kaoru Mogushi; Mio Tajiri; Satoru Ishibashi; Itsuki Ajioka; Kinya Ishikawa; Hidehiro Mizusawa; Shigeo Murayama; Takanori Yokota
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

Review 7.  Nanomedicine applications in women's health: state of the art.

Authors:  Oliver Lloyd-Parry; Charlotte Downing; Eisa Aleisaei; Celine Jones; Kevin Coward
Journal:  Int J Nanomedicine       Date:  2018-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.